10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
US precision medicines company IDEAYA Biosciences saw its shares leap 15.5% to $3.50 by mid-day, after it revealed a clinical trial collaboration with pharma giant Pfizer. 18 March 2020
Danish diabetes care giant Novo Nordisk has announced that two Phase III clinical trials and one Phase II trial for concizumab have been paused, due to: “non-fatal thrombotic events” in three patients. 18 March 2020
UK gene and cell therapy company Oxford Biomedica has signed a new licence and clinical supply agreement (LSA) with Juno Therapeutics, a part of Bristol-Myers Squibb. 18 March 2020
Ophthalmic gene therapy company Horama has announced an exclusive licensing agreement for global rights to a program targeting retinal dystrophy associated with pathogenic CRB1 gene mutations. 18 March 2020
US biotech Moderna on Monday announced that the first participant has been dosed in the Phase I study of its mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2). 17 March 2020
Privately-held Singapore-based company Tessa Therapeutics’ CD30-directed autologous CAR-T therapy has received US Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation. 17 March 2020
US biotech Microbiotix has been awarded up to $2.86 million in non-dilutive funding by CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) to develop a new oral antibiotic to treat multidrug-resistant gonorrhea. 17 March 2020
US clinical-stage biotech Provention Bio yesterday announced a temporary pause in the randomization of patients with newly diagnosed type 1 diabetes (T1D) into its global Phase III PROTECT study of PRV-031 (teplizumab. 17 March 2020
Nucala (mepolizumab) has now been approved in Canada as an add-on maintenance treatment for use in adults, adolescents and children (aged six years and older) with severe eosinophilic asthma. 17 March 2020
The Franco-American pairing of Sanofi and Regeneron have rapidly ramped up a coronavirus (COVID-19) trial of Kevzara (sarilumab), a drug that is currently approved for rheumatoid arthritis (RA). 16 March 2020
US drugmakers Eli Lilly and Incyte Corp have announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA). 16 March 2020
A new partnership between Vancouver-based AbCellera and Eli Lilly will use antibodies from former COVID-19 patients as the basis for an antibody therapy for the disease. 16 March 2020
Germany’s Merck and Pfizer today announced a disappointing update from the Phase III JAVELIN head and neck 100 study evaluating avelumab in addition to chemoradiotherapy (CRT) versus standard-of-care CRT in patients with untreated locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). 16 March 2020
Oxford BioDynamics, a UK biotech focused on the discovery and development of biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch, announces that Dr Jon Burrows has been appointed as group chief executive, effective 23 March 2020. 16 March 2020
German newspaper Welt am Sonntag over the weekend said that US President Donald Trump “had offered funds” to entice German mRNA-based drug specialist CureVac to move its recently started COVID-19 R&D work to the USA, and the German government was now “making counter-offers to tempt it to stay.” 16 March 2020
Germany immunotherapeutics firm BioNTech today provided further details on its R&D effort, “Project Lightspeed,” to develop a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease. 16 March 2020